A Novel Mutation in the NAGLU (N-Acetyl-Alpha-Glucosaminidase) Gene Associated With Mucopolysaccharidosis Type III-B in a Saudi Girl

Rawia F. Albar 1, Rahaf A. AlQurashi 2, Nada Naaman 2, Atheer Alghamdi 2, Sara K. Alghamdi 2, Khulud Aljohani 2, Rawaf Alsharif 2

1. Pediatrics, King Abdulaziz Medical City, Jeddah, SAU  2. College of Medicine, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Jeddah, SAU

Corresponding author: Atheer Alghamdi, alghamdiiatheer@gmail.com

Abstract

Mucopolysaccharidosis type III-B (MPS III), also known as Sanfilippo syndrome, is a rare autosomal recessive lysosomal storage disease that primarily affects the brain and spinal cord. In this report, we describe the case of an eight-year-old female child who presented to the emergency room with an asthma exacerbation. She had coarse facial features, thick eyebrows, deep-seated eyes, thinning coarse hair, and macrocephaly. Moreover, she suffered from hepatosplenomegaly, generalized muscular atrophy, global developmental delay, and scoliosis. Urinary glycosaminoglycans (GAGs) were within normal limits. Full genetic testing confirmed the diagnosis of Sanfilippo syndrome type B with a deficiency of alpha-N-acetylglucosaminidase caused by a homozygous mutation c.889C>T, p.(Arg297*) in the NAGLU (N-acetyl-alpha-glucosaminidase) gene. Chromosomal microarray analysis (CMA) showed a copy number variant (CNV) within the 1q24 region. Thus far, CNVs similar in size and position have not been reported in the literature, making this a novel mutation.

Introduction

Mucopolysaccharidoses (MPS) are lysosomal storage diseases characterized by the deficiency of the enzymes required for the degradation of mucopolysaccharides, which are also known as glycosaminoglycans (GAGs) [1]. MPS is classified into several types based on the specific lysosomal enzyme affected. The different MPS subtypes show variable phenotypes and severity [2]. MPS III, also known as Sanfilippo syndrome, is a rare condition that leads to multisystem deterioration including childhood-onset neurodegeneration, organ dysfunction, skeletal deformities, and a usual life expectancy lasting up to the second or third decade of life [3]. The disorder is inherited in an autosomal recessive pattern and is characterized by the accumulation of the mucopolysaccharide, heparan sulfate [3]. MPS III is further subdivided into four subtypes based on the deficient lysosomal enzyme involved. The four enzymes are heparan N-sulfatase, alpha-N-acetylgalactosaminidase, acetyl-CoA-alpha-glucosaminide acetyltransferase, and N-acetylgalactosamine-6-sulfatase [2]. The accumulated heparan sulfate in lysosomes leads to the clinical picture of the disease [1]. A systematic review reported that the lifetime risk at birth for MPS III ranges from 0.17 to 2.35 per 100,000 live births, and in Saudi Arabia, the risk at birth was estimated to be around 2 per 100,000 live births [4]. In this case report, we describe the manifestations of Sanfilippo syndrome type B in an eight-year-old girl of Saudi origin.

Case Presentation

An eight-year-old female child presented to the emergency department with complaints of cough and fever, with a clinical examination consistent with asthma exacerbation. The child was born to consanguineous Saudi parents after a full-term pregnancy and delivered by spontaneous vaginal delivery. The child was born to a 43-year-old mother whose pregnancy was complicated by oligohydramnios at 16 weeks of gestation. The child had intrauterine growth restriction with birth weight (1.6 kg), a delayed first cry, and was admitted to the neonatal intensive care unit and required mechanical ventilation for one month due to respiratory distress syndrome. The patient has three healthy older siblings (one brother and two sisters) and previously had two other sisters who were diagnosed with the same syndrome and died at the ages of 17 and 14 because of bleeding and infection, respectively. The family pedigree is shown in Figure 1.

How to cite this article
Albar R F, AlQurashi R A, Naaman N, et al. (October 20, 2022) A Novel Mutation in the NAGLU (N-Acetyl-Alpha-Glucosaminidase) Gene Associated With Mucopolysaccharidosis Type III-B in a Saudi Girl. Cureus 14(10): e30519. DOI 10.7759/cureus.30519
The patient suffered from multiple comorbid conditions, including congenital cataracts, sensorineural hearing loss, cardiac defects (moderate patent ductus arteriosus, mild pulmonary hypertension, moderate tricuspid regurgitation, mitral stenosis, cardiomegaly, dilated left atrium and ventricle, and subaortic membrane with mild gradient), spasticity, subtle scoliosis, bilateral multicystic kidneys, atopy (bronchial asthma, eczema, and food allergies), and recurrent respiratory tract infections. According to the parents, she has had a global developmental delay with a delay in milestones (started walking at four years of age) and has had a general cognitive decline since birth. Her clinical condition deteriorated over time with oropharyngeal dysphagia and immobility, with a need for assistance for all activities. She had never been to school. The mother denied any aggressive behavior, autism, hyperactivity, sleep disturbance, or seizures.

On examination, her weight was 10.6 kg, and her height was 92 cm, and she was wasted and stunted (BMI = 12.52, below the third percentile). She had coarse facial features, thick eyebrows, deep-seated eyes, thinning coarse hair, and macrocephaly (Figure 2). She had hepatosplenomegaly, generalized muscular atrophy, bilateral flexion contractures of elbows and knees, and scoliosis with fine tremors. Skeletal survey radiography showed diffuse osteopenia and increased trabeculation of the bone. A general laboratory workup revealed anemia and high creatinine levels, most likely due to undernutrition and muscle wasting. The rest of her labs were within normal limits. Radiography of the chest showed cardiomegaly with increased pulmonary vascularity (Figure 3).
The patient was diagnosed with Sanfilippo IIIb at the age of 4 years, urinary GAG test was done for screening purposes. The result of the urinary GAG test was within normal limits. The patient was referred to a geneticist and a whole-exome sequencing (CentoXome Gold ®) uncovered a homozygous mutation c.889C>T, p.(Arg297*) in the NAGLU (N-acetyl-alpha-glucosaminidase) gene confirming the diagnosis of mucopolysaccharidosis type IIIB. This variant has previously been described as disease-causing for Sanfilippo syndrome B by Zhao et al., Yogalingam et al., and de Ruijter et al. [5-7].

Chromosomal microarray analysis (CMA; CentoArrayCyto™-HD incl. SNP test) was performed showing a copy number variant (CNV) within the 1q24 region. So far, CNVs similar in size and position have not been reported in the literature, therefore, making it a novel mutation.

**Discussion**

Only two cases of Sanfilippo syndrome have been reported in Saudi Arabia (types A and D) [8-9]. To the best of our knowledge, this is the first report of Sanfilippo syndrome type B from Saudi Arabia. In Table 1, we
provided a summary of the clinical features previously reported with cases of Sanfilippo syndrome type B syndrome [10-17]. Most of the findings described in our patient were similar to those published in previous case reports. These clinical features include motor and speech development delays; facial dysmorphism, recurrent upper respiratory tract infections, hepatosplenomegaly, and cardiac defects. Besides the presented case, most cases reported in the literature were born to consanguineous parents [11,13,17], highlighting the strong association between consanguineous marriages and autosomal recessive disorders like Sanfilippo syndrome. Patients for whom brain magnetic resonance imaging (MRI) was performed showed similar findings of generalized volume loss. An exception was the study by Rezayi et al. [13], which presented primarily a picture of neurological deficits and a normal brain MRI. In the study by Rezayi et al. [13], the diagnosis of MPS was confirmed by the levels of GAG in the urine.
| Baldini et al. [10] | Elmar et al. [11] | Irgumey et al. [12] | Royaj et al. [13] | Hettiananth et al. [14] | Champion et al. [15] | Aydin et al. [16] | Federico et al. [17] | Our case |
|--------------------|------------------|-------------------|------------------|-------------------|-------------------|------------------|------------------|---------|
| Consanguinity      | -                | +                 | -                | +                 | +                 | +                | +                | +       |
| Pregnancy and delivery complications | -                | -                 | -                | Not reported       | -                 | -                | Not reported     | -       |
| First signs and symptoms | Speech delay and behavioral problems | Speech delay, hepatomegaly, learning disability, pachyonychia congenita, and cataracts with effusion | Speech delay and loss of balance | Speech delay, seizures, and ataxia | Failure to thrive and developmental regression | Behavioral and sleep problems | Speech delay, vomiting, and needlessness | Progressive mental regression and hernias | Speech delay and vomiting |
| Age at diagnosis | Not reported | 9 years | 14 years | Not reported | 4 years | 3 years | Not reported | 6 years |
| Behavioral problems | +                | -                 | +                | +                 | Not reported       | +                | +                | -       |
| Sleep disorders | -                | Not reported       | +                | Not reported       | Not reported       | +                | Not reported     | -       |
| Epilepsy | +                | -                 | -                | Not reported       | Not reported       | +                | Not reported     | +       |
| Hearing problems | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | +       |
| Visual problems | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | +       |
| Dysphagia | Not reported | Not reported | +                | Not reported       | Not reported       | Not reported | Not reported     | +       |
| Loss of sphincter control | Not reported | Not reported | +                | Not reported       | Not reported       | Not reported | Not reported     | +       |
| Joint contractures | -                | -                 | Not reported | Not reported       | Not reported       | Not reported | Not reported     | +       |
| Dysmorphic features | +                | +                 | +                | +                 | Not reported       | +                | +                | +       |
| Skeletal abnormalities | Not reported | -                 | +                | Not reported       | Not reported       | +                | -                | +       |
| Cardiac anomalies | Not reported | -                 | +                | Not reported       | Not reported       | +                | +                | -       |
| Renal anomalies | Not reported | Not reported | Not reported | -                 | Not reported       | Not reported | Not reported     | +       |
| Hepatosplenomegaly | +                | +                 | +                | +                 | Not reported       | +                | +                | +       |
| Atopy | Not reported | Not reported | Not reported | Not reported       | Not reported       | Not reported | Not reported     | +       |
| Recurrent URTIs | Not reported | +                | Not reported | +                 | +                 | +                | Not reported     | +       |
| Urine GAGs test results | +                | +                 | +                | Not reported       | +                 | Not reported     | +                | -       |
| Brain MRI findings | Not reported | +                 | +                | Not reported       | +                 | Not reported     | Unavailable     | +       |

**TABLE 1: Features of Sanfilippo type B as described in the literature and in our case.**

URTIs: upper respiratory tract infections, GAGs: glycosaminoglycans.

One key difference present in our case was the negative urinary GAG test result. All reviewed reports had a positive test, except for the report by Baldini et al., in which the test was ordered when the patient was four years of age [10]. This suggests that a negative urinary GAG test does not rule out the diagnosis, especially when the test is ordered at a young age. Some differences between the cases may be attributed to the progressive nature of the disease. With the accumulation of substances like heparan sulfate, more symptoms may arise with increasing severity.

The variability in investigation results and patients’ presentations could cause a delay in the diagnosis of MPS III. In addition, patients could be misdiagnosed with unspecified metabolic disorders, autism spectrum disorders, epileptic disorders, or global developmental delays. Therefore, besides the clinical presentation,
hospitals should utilize different investigation modalities such as laboratory data, genetic testing, and imaging findings to reach a proper diagnosis in a timely manner.

Conclusions
Sanfilippo syndrome is a rare, progressive, genetic, multisystem, and lysosomal storage disease. While the pathophysiology is still not fully understood, it manifests as a result of the accumulation of glycosaminoglycans in body tissues and cells. Hence, patients typically present with features of developmental delay, speech delay, and intellectual disability. In addition, if clinical and laboratory findings suggest Sanfilippo syndrome in a child, further genetic and molecular testing must be conducted to confirm the diagnosis. In our report, we demonstrate the history and the important clinical findings of Sanfilippo syndrome type IIIB in an eight-year-old girl at King Abdulaziz Medical City-Jeddah, Saudi Arabia. This case report is the first to describe Sanfilippo syndrome type B in Saudi Arabia.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. King Abdullah International Medical Research Center issued approval IRB/0163/22. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Zhou J, Lin J, Leung WT, Wang L: A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020, 9:1-9. 10.5582/irdr.2020.01011
2. Benetó N, Vilageliu L, Grinberg D, Canals I: Sanfilippo syndrome: Molecular basis, disease models and therapeutic approaches. Int J Mol Sci. 2020, 21: 10.3390/ijms21217819
3. Andrade F, Aldámiz-Echevarría L, Llarena M, Couce ML: Sanfilippo syndrome: overall review. Pediatr Int. 2015, 57:331-8. 10.1111/ped.12636
4. Zelei T, Csetneci K, Vokó Z, Siffel C: Epidemiology of Sanfilippo syndrome: results of a systematic literature review. Orphanet J Rare Dis. 2018, 13:55. 10.1186/s13023-018-0796-4
5. Zhao HG, Li HH, Bach G, Schmidtchen A, Neufeld EF: The molecular basis of Sanfilippo syndrome type B. Proc Natl Acad Sci U S A. 1996, 93:6101-5. 10.1073/pnas.93.12.6101

10.1002/aqm.a.56180
6. Yogalingam G, Weber B, Meenan J, Rogers J, Hopwood J: Mucopolysaccharidosis type IIIB: characterization and expression of wild-type and mutant recombinant alpha-N-acetylgalcosaminidase and relationship with sanfilippo phenotype in an attenuated patient. Biochim Biophys Acta. 2000, 15:415-25. 10.1016/S0925-4439(00)00066-1
7. de Ruiter J, de Ru MH, Wagemans T, et al.: Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III. Mol Genet Metab. 2012, 107:705-10. 10.1016/j.ymgme.2012.09.024
8. Mohamed S: Sanfilippo syndrome, glucose-6-phosphate dehydrogenase deficiency and sickle cell B+ thalassemia in a child: the burden of consanguinity. Am J Med Genet A. 2014, 164A:267-9. 10.1002/ajmg.a.36180
9. Ozand PT, Thompson JN, Gaccon GG, Sarvepalli SB, Nester MJ, Brismar J: Sanfilippo type D presenting with acquired language disorder but without features of mucopolysaccharidosis. J Child Neurol. 1994, 9:408-11. 10.1177/088307389400900415
10. Baldini G, Palmejiani J, Sant Anna J, et al.: Sanfilippo Syndrome: The Tale of a Challenging Diagnosis . J Inborn Errors Metab Screen. 2020, 8:10.1590/2326-4594-ijems-2020-0005
11. Elmas M, Gogus B, Kılıçarslan F, Bukulmez A, Solak M: Genotype to phenotype: Identification of mucopolysaccharidosis type IIIB (Sanfilippo’s B) case using whole exome sequencing. J Pediatr Genet. 2021, 10:74-6. 10.1002/jpg.50043
12. Irigoneh AT, Moreira AM, Valle DA, Santos ML: Mucopolysaccharidosis type IIIS misdiagnosed as an autistic spectrum disorder: a case report and literature review. Rev Paul Peadiatr. 2020, 39:e20195397. 10.1590/1984-0462/2020.39.20195397
13. Besavi A, Feeshangchi-Bonab M, Taherian R: An uncommon presentation of mucopolysaccharidosis type IIIB. Iran J Child Neurol. 2019, 13:105-111.
14. Hettiarachchi D, Nethikumara N, Pathirana BA, Weththasigha K, Dissanayake WD, Dissanayake VH: A novel mutation in the NAGLU gene associated with Sanfilippo syndrome type B (mucopolysaccharidosis III B). Clin Case Rep. 2018, 6:1051-4. 10.1002/ccr3.1521
15. Champion K, Bausehorn M, Wood T, Destree A, Vannuffel P, Maystadt I: Identification and characterization of a novel homozygous deletion in the α-N-acetylgalcosaminidase gene in a patient with Sanfilippo syndrome type B (mucopolysaccharidosis IIIB). Mol Genet Metab. 2010, 100:51-56.
16. Aydin M, Akarsu S, Kabakus N, Akpolat N: Mucopolysaccharidosis IIIB, cerebral vasculopathy and recurrent subdural hematoma. Indian Peadiatr. 2006, 43:457-440.
17. Federico A, Capece G, Cecio A, D’Auria N, Di Iorio G, Ronzivalle L, Di Natale P: Sanfilippo B syndrome (MPS III B): case report with analysis of CSF mucopolysaccharides and conjunctival biopsy. J Neurol. 1981, 225:77-83. 10.1007/BF00313521

2022 Albar et al. Cureus 14(10): e30519. DOI 10.7759/cureus.30519 6 of 6